Q32 Bio QTTB

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.04 (-2.56%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Q32 Bio (QTTB) Business Model and Operations Summary
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Key Insights

Q32 Bio (QTTB) Core Market Data and Business Metrics
  • Latest Closing Price

    $1.55
  • Market Cap

    $18.91 Million
  • Total Employees

    29
  • IPO Date

    March 26, 2024
  • SIC Description

    Pharmaceutical Preparations
  • Primary Exchange

    NASDAQ
  • Headquarters

    830 Winter Street, Waltham, MA, 02451

Earnings Reports

Expected vs. Actual Quarterly Earnings-Per-Share & Revenue

Short Volume

Daily short volume activity identifies short-term trading pressure and potential price volatility

Short Interest

Short Interest

This information represents bi-monthly aggregated short interest data reported to the Financial Industry Regulatory Authority (FINRA) by broker-dealers.

Settlement Date: The date on which the short interest data is considered settled, typically based on exchange reporting schedules.

Short Interest: The total number of shares that have been sold short but have not yet been covered or closed out.

Avg Daily Volume: The average daily trading volume for the stock over the specified period, typically used to contextualize short interest.

Days To Cover: The estimated number of days it would take to cover all short positions based on average trading volume.

Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential

Revenue Breakdown

Distribution of revenue across unique business segments & geographies

Historical Stock Splits

Execution DateSplit Amount

Historical Dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about QTTB from trusted financial sources